Prognostic Indicators
A prognosis is a doctor's best estimate of how a disease will affect an individual and how it is likely to respond to treatment.
There are a number of factors that affect the prognosis of a person with multiple myeloma. Some of the most commonly recognized factors are summarized in the chart below.
| Routine laboratory tests | Indicators of more active disease |
|---|---|
| Beta 2 microblobulin (ß2M) | Higher levels |
| Serum albumin | Lower levels |
| Serum creatinine | Higher than normal |
| Lactate dehydrogenase (LD or LHD) | Higher than normal |
| C-reactive proytein (CRP) | Higher than normal |
| Hemoglobin (red blood cells) | Lower than normal |
| Platelet count | Lower than normal |
| Special tests | Indicators of more active disease |
|---|---|
| Plasma cell labeling index (PCLI) | High percentage of plasma cells |
| Plasma cell morphology |
Presence of immature plasma cells (plasmatic morphology) |
|
Chromosome analysis or FISH (cytogenetic testing) |
Absence of chromosome 13 and other cytogenetic abnormalities |
| Bone marrow microvessel density (MVD) | Growth of new blood vessels in the bone marrow |
For more information, download the Multiple Myeloma Patient Handbook
Designed to provide educational support to patients, caregivers, families, and friends, this handbook gives accurate, reliable, and clear information on myeloma. Topics cover its causes and effects, how it is diagnosed, and the treatment options available in Canada.
Download it now.